Edition:
United Kingdom

People: Steadymed Ltd (STDY.OQ)

STDY.OQ on NASDAQ Stock Exchange Global Market

4.68USD
17 Aug 2018
Change (% chg)

$-0.08 (-1.58%)
Prev Close
$4.75
Open
$4.70
Day's High
$4.70
Day's Low
$4.65
Volume
40,300
Avg. Vol
33,372
52-wk High
$6.45
52-wk Low
$2.65

Rigby, Jonathan 

Mr. Jonathan M.N Rigby, MBA, is President, Chief Executive Officer, Director of the Company. Since March 2016, Mr. Rigby has been a member of the board of directors of Xeris Pharmaceuticals, Inc., a privately-held specialty biopharmaceutical company. In 2006 Mr. Rigby cofounded Zogenix, Inc. a specialty pharmaceutical company focused on the development and commercialization of CNS and pain products where he served as the company's Vice President of Business Development until December 2010. As a member of the senior management team he played an important role in the development, approval and U.S. launch of the world's first needle free drug device combination product to treat migraine. Between 2002 and 2006 Mr. Rigby held positions of increasing responsibility at Aradigm Corporation, including Vice President of Business Development where he was involved in M&A activities as well as inhalation delivery technology licensing in various therapeutic fields including Pulmonary Arterial Hypertension, or PAH. Between 1995 and 2002 Mr. Rigby held various commercial and business development positions at Profile Therapeutics, UK, where he played a key role in the licensing of inhalation technology that resulted in the approval and launch of an inhalation product to treat PAH. Between 1990 and 1995 he held various sales and marketing positions at large pharmaceutical companies including Merck Sharpe and Dohme, or MSD, and Bristol Myers Squibb, or BMS. Mr. Rigby has a Bachelor of Science Degree, with Honors, in Biological Sciences from Sheffield University, UK, and an MBA from Portsmouth University.

Basic Compensation

Total Annual Compensation, USD 431,200
Restricted Stock Award, USD 342,500
Long-Term Incentive Plans, USD --
All Other, USD 107,800
Fiscal Year Total, USD 881,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --